Ad
Wednesday, 20 September 2017
GSK's new triple lung drug beats other modern inhalers in study
LONDON (Reuters) - GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment